What is the recommended steroid for treating Crohn's disease exacerbation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Steroids for Crohn's Disease Exacerbation

For Crohn's disease exacerbation, oral prednisone 40-60 mg/day is recommended as the first-line steroid therapy for moderate to severe disease, while budesonide 9 mg/day is recommended for mild to moderate disease limited to the ileum and/or right colon. 1

Steroid Selection Based on Disease Severity and Location

Mild to Moderate Disease

  • For mild to moderate ileal and/or right colonic Crohn's disease, oral budesonide 9 mg/day is suggested as first-line therapy to induce remission 1
  • Budesonide should be evaluated for response between 4-8 weeks to determine need for therapy modification 1
  • Budesonide has fewer systemic side effects compared to conventional corticosteroids due to its high first-pass metabolism in the liver 2

Moderate Disease After Budesonide Failure

  • In patients with moderate Crohn's disease who have failed to respond to oral budesonide 9 mg/day, prednisone 40-60 mg/day is suggested to induce complete remission 1

Moderate to Severe Disease

  • For moderate to severe Crohn's disease, oral prednisone 40-60 mg/day is strongly recommended to induce complete remission 1
  • Response to prednisone should be evaluated between 2-4 weeks to determine need for therapy modification 3
  • Prednisone has been shown to induce remission in 60-83% of patients with moderate to severe Crohn's disease 1

Severe Disease Requiring Hospitalization

  • For patients with active Crohn's disease severe enough to require hospitalization, intravenous corticosteroids (e.g., methylprednisolone 40-60 mg/day) are suggested to induce symptomatic remission 4
  • Patients with severe disease should be evaluated for response to IV methylprednisolone within 1 week 5

Important Considerations and Limitations

Duration of Therapy

  • Steroids should be used for short-term induction of remission only 5
  • Approximately 50% of patients will either fail to respond (steroid-resistant) or become steroid-dependent at 1 year 4
  • Steroids are not effective for maintenance of remission in Crohn's disease of any severity 2

Side Effects and Monitoring

  • Corticosteroid-associated side effects include moon face, acne, infection, hypertension, glucose intolerance, osteoporosis, and psychiatric disturbances 6
  • Budesonide has significantly fewer corticosteroid-associated side effects compared to prednisolone (33% vs 55%) 2
  • Morning plasma cortisol concentrations are less suppressed with budesonide compared to prednisolone 2

Steroid-Sparing Strategies

  • For patients requiring repeated courses of steroids, consider steroid-sparing agents such as thiopurines, methotrexate, or biologics 6
  • In selected patients who achieve remission on corticosteroids, thiopurine monotherapy or methotrexate may be used to maintain remission [@16@, @18@]
  • Anti-TNF therapy (infliximab, adalimumab) is recommended for patients with moderate to severe disease who fail to achieve remission with corticosteroids [@21@]

Common Pitfalls to Avoid

  • Avoid using steroids for maintenance therapy as they are ineffective and associated with significant long-term adverse effects 2
  • Do not use doses of prednisolone less than 15 mg/day for active disease as they are ineffective 1
  • Avoid too rapid reduction of steroid dose as this can be associated with early relapse 1
  • Do not continue ineffective steroid therapy without reassessment - evaluate response within the recommended timeframes and modify therapy if needed 3, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A comparison of budesonide with prednisolone for active Crohn's disease.

The New England journal of medicine, 1994

Research

Review article: appropriate use of corticosteroids in Crohn's disease.

Alimentary pharmacology & therapeutics, 2007

Research

Review article: the limitations of corticosteroid therapy in Crohn's disease.

Alimentary pharmacology & therapeutics, 2001

Research

Steroid-dependent Crohn's disease.

Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.